يتناول هذا البروتوكول داء الباراكوكسيديويدوميكوسيس في صورته السريرية المعتدلة — التي تتميز بنمط محدد من فقدان الوزن والنتائج المصلية — ويحدد نهج العلاج المنظَّم المنطبق على هذه الفئة من المرضى.
DOI: 10.1590/S0036-46652015000700007
In severe infections, patients present ≥ 3 of the criteria above mentioned; in the moderate form, total body weight loss ranges between 5 and 10% and the counter immunoelectrophoresis titers are between 1/16–1/32.
Recommended treatment for moderate or severe cases of PCM consists in two steps: a) an induction phase to control clinical symptoms until acute phase laboratory parameters return to normal; b) a maintenance phase up to the interruption of treatment based on immunological and other laboratory inflammation markers such as acute phase proteins.
Once the acute phase is under control, the treatment can be changed to oral drugs (once or twice daily), favoring the adherence to longer treatment regimens. For long term treatments, 6–12 months are required for induction and 12–24 months for maintenance.
View source ↗